Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TNFAIP3 |
| Gene Name: | TNFAIP3 |
| Protein Full Name: | Tumor necrosis factor alpha-induced protein 3 |
| Alias: | A20; DNA binding protein A20; EC 3.-.-.-; OTUD7C; TNAP3; TNFA1P2; Zinc finger protein A20 |
| Mass (Da): | 89614 |
| Number AA: | 790 |
| UniProt ID: | P21580 |
| Locus ID: | 7128 |
| COSMIC ID: | TNFAIP3 |
| Gene location on chromosome: | 6q23.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 22132 |
| Percent of cancer specimens with mutations: | 1.77 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with point mutations, complex mutations, insertions and deletions over entire protein length. |
| Normal role description: | Ubiquitination protein. Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signalling pathways. Upon TNF stimulation, deubiquitinates 'Lys-63'-polyubiquitin chains on RIPK1 and catalyzes the formation of 'Lys-48'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. In vitro able to deubiquitinate both 'Lys-48'- and 'Lys-63' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. |